These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2390644)

  • 1. IL-2 activated cell-mediated immunotherapy: control of minimal residual disease in malignant disorders by allogeneic lymphocytes and IL-2.
    Slavin S; Ackerstein A; Kedar E; Weiss L
    Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():86-90. PubMed ID: 2390644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines.
    Slavin S; Ackerstein A; Weiss L; Nagler A; Or R; Naparstek E
    Cancer Invest; 1992; 10(3):221-7. PubMed ID: 1581831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
    Weiss L; Reich S; Slavin S
    Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated immunotherapy.
    Weiss L; Reich S; Slavin S
    Cancer Invest; 1992; 10(1):19-26. PubMed ID: 1735011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia.
    Weiss L; Reich S; Slavin S
    Cytokines Cell Mol Ther; 1999 Sep; 5(3):153-8. PubMed ID: 10641573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disease in malignant hematologic disorders.
    Ackerstein A; Kedar E; Slavin S
    Blood; 1991 Sep; 78(5):1212-5. PubMed ID: 1878588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation.
    Zeis M; Uharek L; Glass B; Vosskötter W; Dreger P; Schmitz N; Steinmann J
    Exp Hematol; 1998 Oct; 26(11):1068-73. PubMed ID: 9766447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of recombinant cytokines and other immunomodulators on engraftment following allogeneic bone marrow transplantation in mice.
    Bieder A; Weiss L; Slavin S
    Bone Marrow Transplant; 1992 Jun; 9(6):421-6. PubMed ID: 1628125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy in conjunction with autologous bone marrow transplantation.
    Eckerstein A; Slavin S; Weiss L; Naparstek E
    Bone Marrow Transplant; 1990 Jan; 5 Suppl 1():38. PubMed ID: 2317604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of graft-versus-leukemia (GVL) activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts.
    Zeis M; Uharek L; Glass B; Gaska T; Gassmann W; Mueller-Ruchholtz W
    Bone Marrow Transplant; 1994 Nov; 14(5):711-5. PubMed ID: 7889004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study on nonmyeloablative allogeneic bone marrow transplantation in the treatment of L615 leukemia mice].
    Xu KL; Ju JP; Pan XY; Du B; Li ZY; Lu QX
    Zhonghua Xue Ye Xue Za Zhi; 2003 Jul; 24(7):372-5. PubMed ID: 12941194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.
    Cohen P; Vourka-Karussis U; Weiss L; Slavin S
    J Immunol; 1993 Nov; 151(9):4803-10. PubMed ID: 8409438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapeutic aspects of allogeneic peripheral progenitor cells.
    Glass B; Uharek L; Hartung G; Zeis M; Steinmann J; Dreger P; Krönke M; Schmitz N
    Bone Marrow Transplant; 1998 Jun; 21 Suppl 3():S3-8. PubMed ID: 9712483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
    Johnson BD; Drobyski WR; Truitt RL
    Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression and elimination of BCL1 leukemia by allogeneic bone marrow transplantation.
    Weiss L; Morecki S; Vitetta ES; Slavin S
    J Immunol; 1983 May; 130(5):2452-5. PubMed ID: 6339628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of GVL effect with rhIL-2 following BMT in a murine model for acute myeloid leukemia in SJL/J mice.
    Vourka-Karussis U; Karussis D; Ackerstein A; Slavin S
    Exp Hematol; 1995 Mar; 23(3):196-201. PubMed ID: 7875238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Graft-versus-leukemia effects from donor lymphocyte infusion after nonmyeloablative allogeneic bone marrow transplantation in mice.
    Du B; Li DP; Xu KL; Pan XY
    Chin Med J (Engl); 2005 Mar; 118(6):474-9. PubMed ID: 15788128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Experimental study on immunotherapy with dendritic cell in leukemic mice model].
    Li XX; Chen XL; Ma DX; Liu CS; He XP
    Zhonghua Xue Ye Xue Za Zhi; 2006 Feb; 27(2):73-7. PubMed ID: 16732955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic cell-mediated immunotherapy of leukemia with immune donor lymphocytes to upregulate antitumor effects and downregulate antihost responses.
    Ji YH; Weiss L; Zeira M; Abdul-Hai A; Reich S; Schuger L; Slavin S
    Bone Marrow Transplant; 2003 Sep; 32(5):495-504. PubMed ID: 12942096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.